PDF herunterladen
CC BY 4.0 · TH Open 2019; 03(01): e64-e66
DOI: 10.1055/s-0039-1683969
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia

Francesca Martini
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
,
Nadia Cecconi
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
,
Aldo Paolicchi
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
,
Sara Galimberti
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
,
Giulia Cervetti
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
,
Gabriele Buda
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
,
Mario Petrini
1   Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

04. Dezember 2018

08. Februar 2019

Publikationsdatum:
19. März 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Abnormal coagulation properties indicative of a dysfibrinogenemia were found in the plasma of an asymptomatic 65-year-old male. An immunoglobulin k light chain was found to interfere with Fg functional assay and coagulation tests (activated partial thromboplastin time, prothrombin time, and thrombin time). Steroid therapy reduced the inhibitory effect (after dexamethasone treatment coagulation test and functional Fg value normalized). Spurious dysfibrinogenemia associated with light chain monoclonal gammopathy of undetermined significance was diagnosed.

Keywords

coagulation factors - inhibitor - fibrinogen - fibrin
 

  • References

  • 1 Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29 (03) 177-188
    Suche in Google Scholar
  • 2 Casini A, Blondon M, Tintillier V. , et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost 2018; 118 (11) 1867-1874
    Thieme ConnectPubMedSuche in Google Scholar
  • 3 Casini A, Blondon M, Lebreton A. , et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125 (03) 553-561
    CrossrefPubMedSuche in Google Scholar
  • 4 Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994; 78 (03) 545-554
    CrossrefPubMedSuche in Google Scholar
  • 5 Post GR, James L, Alapat D, Guillory V, Cottler-Fox M, Nakagawa M. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Transfus Apheresis Sci 2013; 48 (01) 35-38
    CrossrefPubMedSuche in Google Scholar
  • 6 National Committee for Clinical Laboratory Standards. NCCLS Document H30-A: Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 1994
    Suche in Google Scholar
  • 7 Palareti G, Maccaferri M, Manotti C. , et al; C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. Fibrinogen assays: a collaborative study of six different methods. Clin Chem 1991; 37 (05) 714-719
    CrossrefPubMedSuche in Google Scholar
  • 8 Dear A, Brennan SO, Sheat MJ, Faed JM, George PM. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain. Haematologica 2007; 92 (11) e111-e117
    CrossrefPubMedSuche in Google Scholar
  • 9 Llobet D, Borrell M, Vila L, Vallvé C, Felices R, Fontcuberta J. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient. Haematologica 2007; 92 (02) e17-e19
    CrossrefPubMedSuche in Google Scholar
  • 10 Kotlín R, Sobotková A, Riedel T. , et al. Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol 2008; 120 (02) 75-81
    CrossrefPubMedSuche in Google Scholar